ALVOW
Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS
$0.17
+9.96%Price chart
Sep 18Sep 25Oct 1Oct 6Oct 12Oct 26Oct 30Nov 4
Key dataNov 4, 2026
Open$0.17
From 52W high−91.54%
Volume11200.00
Market cap$49.56M
P/E (TTM)—
P/S (TTM)0.1x
Div yield—
Key dataNov 4, 2026
Open
$0.17
From 52W high
−91.54%
Volume
11200.00
Market cap
$49.56M
ValuationView details →
P/E (Fwd)
1.1x
EV/EBITDA
208.0x
P/E (TTM)
—
RSI (14)
42.6
MomentumView details →
1D Return
+9.96%
YTD Return
−76.90%
Similar companies
Latest newsMore news →
Alvotech announced that it will release its financial results for the nine months and third quarter ended September 30, 2026, on November 11, 2026, after the U.S. market close.7d agoThe U.S. Food and Drug Administration approved Alvotech’s new manufacturing process for SIMLANDI, which more than doubles output per batch.15d agoAlvotech and Advanz Pharma Corp. Ltd. announced that AVT29 was submitted to the EUROPEAN MEDICINES AGENCY as a line extension to the existing marketing authorization for Mynzepli (aflibercept 2 mg).21d ago